Skip to main content Help with accessibility Skip to main navigation

Tofacitinib

Indication

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA543)

NICE TA 543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Red

Brand:

Xeljanz

Nice TA:

543

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:
• it is used as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
• TNF alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE’s technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Tofacitinib is only recommended if the company provides it according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Nov - 2018